Live Earnings Conference Call: ACADIA Pharmaceuticals will host a live Q1 2026 earnings call on May 6, 2026 at 4:30PM ET. Get details.

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

$22.35 +0.16 (+0.72%)

Closing price 05/5/2026 04:00 PM Eastern

Extended Trading

$22.37 +0.02 (+0.09%)

As of 05/5/2026 07:45 PM Eastern

Compare

ACADIA Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
1

Hold
4

Buy
15

Based on 20 Wall Street analysts who have issued ratings for ACADIA Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 1 has given a sell rating, 4 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for ACAD.

Consensus Price Target

$31.21
39.64% Upside

According to the 20 analysts' twelve-month price targets for ACADIA Pharmaceuticals, the average price target is $31.21. The highest price target for ACAD is $40.00, while the lowest price target for ACAD is $17.00. The average price target represents a forecasted upside of 39.64% from the current price of $22.35.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ACAD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ACADIA Pharmaceuticals and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACAD Analyst Ratings Over Time

Type	Current Forecast 5/6/25 to 5/6/26	1 Month Ago 4/6/25 to 4/6/26	3 Months Ago 2/5/25 to 2/5/26	1 Year Ago 5/6/24 to 5/6/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	11 Buy rating(s)	8 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)	8 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$31.21	$31.21	$30.89	$23.87
Forecasted Upside	39.64% Upside	39.83% Upside	31.69% Upside	64.14% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ACAD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ACAD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ACADIA Pharmaceuticals Stock vs. The Competition

Type	ACADIA Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	39.64% Upside	938.23% Upside	14.74% Upside
News Sentiment Rating	Neutral News See Recent ACAD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/1/2026	Weiss Ratings Not Rated		Downgrade	Hold (C+) ➝ Hold (C)
3/25/2026	Bank of America 4 of 5 stars	Tazeen Ahmad 5 of 5 stars	Upgrade	Neutral ➝ Buy	$29.00	+38.36%
3/4/2026	JPMorgan Chase & Co. 3 of 5 stars	Tessa Romero Not Rated	Boost Target	Overweight	$31.00 ➝ $34.00	+46.24%
2/26/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ritu Baral Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$35.00 ➝ $37.00	+56.35%
2/26/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$31.00 ➝ $30.00	+20.89%
2/26/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason N. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Market Outperform	$34.00 ➝ $35.00	+47.06%
2/26/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$25.00 ➝ $24.00	-4.18%
2/23/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rudy Li Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$33.00	+33.44%
2/23/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Uy Ear Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$29.00 ➝ $35.00	+45.89%
2/6/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform

2/3/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ananda Ghosh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$37.00	+41.60%
1/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ashwani Verma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$35.00 ➝ $40.00	+50.40%
1/6/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yigal Nochomovitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$33.00 ➝ $36.00	+37.67%
1/5/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ami Fadia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$34.00	+29.33%
12/16/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$37.00	+35.73%
9/25/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$29.00	+36.73%
8/7/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sell	$15.00 ➝ $17.00	-28.83%
6/5/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	J. Kim Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
5/20/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeffrey Hung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Equal Weight	$20.00 ➝ $24.00	+9.14%
5/19/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joel Beatty Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$28.00 ➝ $31.00	+42.46%
5/19/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan David Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$24.00 ➝ $28.00	+27.60%
1/3/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yatin Suneja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$23.00 ➝ $20.00	+7.18%
10/10/2024	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:24 AM ET.

ACAD Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for ACADIA Pharmaceuticals is $31.21, with a high forecast of $40.00 and a low forecast of $17.00.
: 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There is currently 1 sell rating, 4 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACAD shares.
: According to analysts, ACADIA Pharmaceuticals's stock has a predicted upside of 39.64% based on their 12-month stock forecasts.
: Over the previous 90 days, ACADIA Pharmaceuticals's stock had 2 upgrades and 1 downgrade by analysts.
: ACADIA Pharmaceuticals has been rated by research analysts at Bank of America, Citizens Jmp, JPMorgan Chase & Co., Mizuho, Oppenheimer, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Weiss Ratings, and Wolfe Research in the past 90 days.
: Analysts like ACADIA Pharmaceuticals more than other "medical" companies. The consensus rating for ACADIA Pharmaceuticals is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ACAD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With ACADIA Pharmaceuticals Recommendations

This page (NASDAQ:ACAD) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

ACADIA Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ACAD Analyst Ratings Over Time

ACAD Analyst Recommendations By Month

ACAD Price Targets by Month

ACADIA Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

ACAD Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With ACADIA Pharmaceuticals Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

ACADIA Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ACAD Analyst Ratings Over Time

ACAD Analyst Recommendations By Month

ACAD Price Targets by Month

ACADIA Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

ACAD Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With ACADIA Pharmaceuticals Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools